Our pipeline is comprised of innovative drug candidates in the fields of Hemostasis and Thrombosis. Some of these compounds, as our recently Orphan Drug Designated TT-103MH
recombinant protein, are available for licensing out. We also have new anticoagulants, antifibrinolytics, antiplatelet agents, and are working on innovative gene therapies for the treatment
of coagulation disorders (Hemophilia
, von Willebrand disease, etc).
Novel and significantly radical approach for the treatment of bleeding disorders, using a topical formulation. See all antihemorrhagic information
of new discover TT-103MH for bleeding disorders.